World's Best Scientists 2026 revealed!
Hans-Juergen Woerle

Hans-Juergen Woerle

D-Index & Metrics

Medicine

D-Index
88
Citations
43599
World Ranking
12928
National Ranking
180

Hans-Juergen Woerle publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Hans-Juergen Woerle sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 281 publications — 13th percentile

13% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Hans-Juergen Woerle D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Hans-Juergen Woerle sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Hans-Juergen Woerle is affiliated with Nestlé (Switzerland) based in Switzerland. Their research primarily focuses on medicine, with specific concentration in the subfields of endocrinology, diabetes, and metabolism, as well as surgery.

The scientific topics addressed in their work include diabetes treatment and management, pancreatic function and diabetes, and diabetes management and research.

Woerle's recent publication record includes the paper titled "Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?" published in 2020 in the journal Diabetes Obesity and Metabolism.

  • Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels? (2020, Diabetes Obesity and Metabolism)

Their frequent co-authors include:

  • Ruth L. Coleman
  • Alastair Gray
  • Uli C. Broedl
  • David Fitchett
  • Jyothis T. George

Woerle's publications have appeared in venues such as Diabetes Obesity and Metabolism, reflecting their specialized interest in diabetes and metabolic disorders.

Best Publications

  • Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

    Bernard Zinman;Christoph Wanner;John M. Lachin;David Fitchett

  • Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

    David Z.I. Cherney;Bruce A. Perkins;Nima Soleymanlou;Maria Maione

  • Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

    Ele Ferrannini;Elza Muscelli;Silvia Frascerra;Simona Baldi

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

    Julio Rosenstock;Vlado Perkovic;Odd Erik Johansen;Mark E. Cooper

  • Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

    David Fitchett;Bernard Zinman;Bernard Zinman;Christoph Wanner;John M. Lachin

  • Renal Gluconeogenesis Its importance in human glucose homeostasis

    John E. Gerich;Christian Meyer;Hans J. Woerle;Michael Stumvoll

  • Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

    Anthony H Barnett;Ambrish Mithal;Jenny Manassie;Russell Jones

  • Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.

    Julio Rosenstock;Steven E. Kahn;Odd Erik Johansen;Bernard Zinman;Bernard Zinman

  • Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

    Robert J Chilton;I. Tikkanen;C. P. Cannon;S. Crowe

  • Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

    Michael Roden;Jianping Weng;Jens Eilbracht;Bruno Delafont

  • Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

    Ilkka Tikkanen;Kirsi Narko;Cordula Zeller;Alexandra Green

  • SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

    Silvio E Inzucchi;Bernard Zinman;Christoph Wanner;Roberto Ferrari

  • The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.

    David Zi Cherney;Bruce A Perkins;Nima Soleymanlou;Ronnie Har

  • Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

    Christoph Wanner;John M. Lachin;Silvio E. Inzucchi;David Fitchett

  • 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

    Baptist Gallwitz;Julio Rosenstock;Thomas Rauch;Sudipta Bhattacharya

  • Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.

    C. S. Kovacs;V. Seshiah;R. Swallow;R. Jones

  • Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

    Hans-Ulrich Häring;Ludwig Merker;Elke Seewaldt-Becker;Marc Weimer

  • Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

    Hans-Ulrich Häring;Ludwig Merker;Elke Seewaldt-Becker;Marc Weimer

  • Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

    Julio Rosenstock;Ante Jelaska;Guillaume Frappin;Afshin Salsali

  • Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

    S. Del Prato;A. H. Barnett;H. Huisman;D. Neubacher

Frequent Co-Authors

Bernard Zinman
Bernard Zinman University of Toronto
Silvio E. Inzucchi
Silvio E. Inzucchi Yale University
John E. Gerich
John E. Gerich Mayo Clinic
Julio Rosenstock
Julio Rosenstock The University of Texas Southwestern Medical Center
Christoph Wanner
Christoph Wanner University of Würzburg
John M. Lachin
John M. Lachin George Washington University
Anthony H. Barnett
Anthony H. Barnett University of Birmingham
Per-Henrik Groop
Per-Henrik Groop University of Helsinki
Mark E. Cooper
Mark E. Cooper Monash University
Darren K. McGuire
Darren K. McGuire The University of Texas Southwestern Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a medical career in the USA opens many doors beyond a traditional MD. Many students choose alternative healthcare pathways that can be pursued through flexible online degrees. For those drawn to patient care, a nursing degree online provides an accessible route into the field, especially for those managing work and study.

If you are already working as a registered nurse and want to enhance your qualifications, affordable rn to bsn programs help nurses advance their careers and qualify for leadership roles. For those interested in research or teaching, there are phd nursing programs online with flexible schedules and lower costs.

Not a nurse yet? Non-nurses with a bachelor’s degree can explore direct entry np programs for non nurses online, which fast-track graduates into advanced nursing practice. Each pathway offers unique opportunities to enter or progress in the US healthcare sector, making online study an increasingly popular and practical choice.

Best Scientists Citing Hans-Juergen Woerle

Trending Scientists

Recently Published Articles